Biome Australia Ltd
BIO
Company Profile
Business description
Biome Australia Ltd licences, develops, and markets evidence-based, complementary medicines, including nutraceuticals vitamins and weight management products and live biotherapeutics. The company has one operating segment: researching, developing, manufacturing and distributing evidence-based products linking the gut and human health. Domestically it caters to Australia and In international markets, the Group distributes and markets its Activated Probiotics range in the United Kingdom and New Zealand through independent health practitioners.
Contact
192-194 Johnston Street
CollingwoodVIC3066
AUST: +61 390175800
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
30 June 2026
Employees
30
Stocks News & Analysis
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.
stocks
Top stocks of the year: Which opportunities remain in 2026?
A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,085.10 | 36.30 | 0.40% |
| CAC 40 | 7,993.49 | 52.31 | -0.65% |
| DAX 40 | 23,591.03 | 224.72 | -0.94% |
| Dow JONES (US) | 47,289.31 | 665.43 | -1.39% |
| FTSE 100 | 10,284.75 | 129.19 | -1.24% |
| HKSE | 25,757.29 | 435.95 | 1.72% |
| NASDAQ | 22,479.79 | 269.20 | -1.18% |
| Nikkei 225 | 55,620.84 | 342.78 | 0.62% |
| NZX 50 Index | 13,519.35 | 98.54 | -0.72% |
| S&P 500 | 6,742.43 | 88.28 | -1.29% |
| S&P/ASX 200 | 8,851.00 | 25.80 | 0.29% |
| SSE Composite Index | 4,124.19 | 15.63 | 0.38% |